Two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. Plenary Posters are highly ranked poster presentations selected by the ASBMR program committee to be presented at the Welcome Reception and Plenary Poster Session of the ASBMR 2026 Annual Meeting.

EB613 is being developed as the first oral anabolic (bone forming) tablet treatment for osteoporosis. The Phase 2 study (Tripto-Shkolnik 2024) randomized 161 postmenopausal women with low bone mass or osteoporosis to placebo or four EB613 dose levels for 6 months. Entera is planning to conduct a single, randomized, double-blind, placebo-controlled, Phase 3 trial of EB613 in approximately 750 postmenopausal women with osteoporosis to support a potential New Drug Application (NDA) submission for EB613 for the treatment of women with postmenopausal osteoporosis. To explore the anabolic effect of EB613 in postmenopausal women with osteoporosis (baseline T-score of ≤-2.5), a post-hoc sensitivity analysis evaluating the relationship between baseline T-score severity and EB613 effects on Bone Mineral Density (BMD) and Bone Turnover Markers (BTM) at 6 months was conducted.

Abstract Title: EB613, Oral PTH(1-34) Tablet, Shows Markedly Enhanced Anabolic Effects in Postmenopausal Women with Osteoporosis at High Risk of Fracture: Insights from Phase 2 Trial

Session Title: Welcome Reception and Plenary Poster Session (Plenary Poster Presentation)

Presentation Number: Fri-026

Session Date/Time: Friday, October 9, 2026, 5:30–7:00 p.m. ET

Session Title: Poster Session II

Presentation Number: Sun-026

Session Date/Time: Sunday, October 11, 2026, 2:00–3:30 p.m. ET